In the face of the COVID-19 pandemic which has taken the world by storm, the lack of approved treatments targeted towards coronavirus has left physicians worldwide grappling with the situation. To help them navigate the black box of COVID-19 management, the ACP* has released a behemoth 28-chapter guide to arm physicians in the virus-infested battle field.
Acne is a common skin problem seen in primary care. Dr Wong
Soon Tee of Assurance Skin Clinic at Mt Elizabeth Novena Hospital, Singapore
shares his insights with Pearl Toh on how to manage acne in the primary care
Post hoc analyses of the LIBERTY AD SOLO 1 & 2* and ADOL** trials demonstrated significant reductions in pruritus, anxiety, and depression with dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis (AD).
Treatment with baricitinib led to clinically meaningful improvements in itch and skin symptoms in patients with moderate-to-severe atopic dermatitis (AD), even in those with additional comorbid atopic conditions, according to a pooled analysis of two phase III studies released in the AAAAI 2020 Meeting.
A customized nanotextile garment for wet wrap therapy (WWT) for moderate-to-severe atopic dermatitis (AD) was as effective as viscose yet superior in terms of patient acceptability, a Singapore study has shown.
The novel, high-affinity, monoclonal antibody lebrikizumab demonstrated significant efficacy in a dose-dependent manner across a range of clinical manifestations of moderate-to-severe atopic dermatitis (AD), including pruritus and quality of life (QoL), a phase IIb study has shown.